{"id":"https://openalex.org/W2072946946","doi":"https://doi.org/10.1016/0014-2999(84)90635-6","title":"A physiological role for dopamine as modulator of GABA effects in substantia nigra: Supersensitivity in 6-hydroxydopamine-lesioned rats","display_name":"A physiological role for dopamine as modulator of GABA effects in substantia nigra: Supersensitivity in 6-hydroxydopamine-lesioned rats","publication_year":1984,"publication_date":"1984-10-01","ids":{"openalex":"https://openalex.org/W2072946946","doi":"https://doi.org/10.1016/0014-2999(84)90635-6","mag":"2072946946","pmid":"https://pubmed.ncbi.nlm.nih.gov/6439567"},"language":"en","primary_location":{"id":"doi:10.1016/0014-2999(84)90635-6","doi":"https://doi.org/10.1016/0014-2999(84)90635-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0014-2999(84)90635-6","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111057576","display_name":"Barbara L. Waszczak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210110767","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210110767"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B.L. Waszczak","raw_affiliation_strings":["Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Building 10, Room 5C103, Bethesda, MD 20205, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Building 10, Room 5C103, Bethesda, MD 20205, U.S.A","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210110767"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034511392","display_name":"Judith R. Walters","orcid":"https://orcid.org/0000-0002-9192-5222","observed_orcids":["https://orcid.org/0000-0002-9192-5222"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210110767","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210110767"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"J.R. Walters","raw_affiliation_strings":["Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Building 10, Room 5C103, Bethesda, MD 20205, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Building 10, Room 5C103, Bethesda, MD 20205, U.S.A","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210110767"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5034511392"],"corresponding_institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210110767"],"apc_list":{"value":3230,"currency":"USD","value_usd":3230},"apc_paid":null,"fwci":0.98,"has_fulltext":false,"cited_by_count":30,"citation_normalized_percentile":{"value":0.70704317,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"105","issue":"3-4","first_page":"369","last_page":"373"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.4542999863624573,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.4542999863624573,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.38260000944137573,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.09130000323057175,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dopamine","display_name":"dopamine","score":0.9860000014305115},{"id":"https://openalex.org/keywords/gaba","display_name":"GABA","score":0.9419999718666077},{"id":"https://openalex.org/keywords/substantia-nigra-pars-reticulata","display_name":"substantia nigra pars reticulata","score":0.9829999804496765},{"id":"https://openalex.org/keywords/6-ohda-lesion","display_name":"6-hydroxydopamine lesion","score":0.859000027179718},{"id":"https://openalex.org/keywords/dopamine-deficiency","display_name":"dopamine deficiency","score":0.5289999842643738},{"id":"https://openalex.org/keywords/supersensitivity","display_name":"supersensitivity","score":0.7609999775886536},{"id":"https://openalex.org/keywords/iontophoresis","display_name":"iontophoresis","score":0.6930000185966492}],"concepts":[{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.9203165769577026},{"id":"https://openalex.org/C2911016594","wikidata":"https://www.wikidata.org/wiki/Q15946111","display_name":"Hydroxydopamine","level":4,"score":0.89525306224823},{"id":"https://openalex.org/C2780938664","wikidata":"https://www.wikidata.org/wiki/Q753278","display_name":"Substantia nigra","level":4,"score":0.844560444355011},{"id":"https://openalex.org/C17077164","wikidata":"https://www.wikidata.org/wiki/Q1185869","display_name":"Inhibitory postsynaptic potential","level":2,"score":0.5684775710105896},{"id":"https://openalex.org/C2777288102","wikidata":"https://www.wikidata.org/wiki/Q780181","display_name":"Oxidopamine","level":5,"score":0.5566486120223999},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.5299233794212341},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5234070420265198},{"id":"https://openalex.org/C2776219046","wikidata":"https://www.wikidata.org/wiki/Q162657","display_name":"Neurotransmitter","level":3,"score":0.43116170167922974},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.427107572555542},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4229491353034973},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.27427488565444946},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.2675434350967407},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23091483116149902},{"id":"https://openalex.org/C529278444","wikidata":"https://www.wikidata.org/wiki/Q47273","display_name":"Central nervous system","level":2,"score":0.16357624530792236}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004298","descriptor_name":"Dopamine","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D005680","descriptor_name":"gamma-Aminobutyric Acid","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006892","descriptor_name":"Hydroxydopamines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011919","descriptor_name":"Rats, Inbred Strains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011954","descriptor_name":"Receptors, Dopamine","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D013378","descriptor_name":"Substantia Nigra","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016627","descriptor_name":"Oxidopamine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/0014-2999(84)90635-6","doi":"https://doi.org/10.1016/0014-2999(84)90635-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0014-2999(84)90635-6","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},{"id":"pmid:6439567","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/6439567","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.5683000087738037}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1981609060","https://openalex.org/W1992603366","https://openalex.org/W1996581608","https://openalex.org/W2033819056","https://openalex.org/W2034991193","https://openalex.org/W2062359923","https://openalex.org/W2072607310","https://openalex.org/W2087258417","https://openalex.org/W2272532664","https://openalex.org/W4407042004"],"related_works":["https://openalex.org/W2087258417","https://openalex.org/W1854009736","https://openalex.org/W1995750091","https://openalex.org/W2063239793","https://openalex.org/W7096567374","https://openalex.org/W2480335370","https://openalex.org/W7097539391","https://openalex.org/W2034991193","https://openalex.org/W2013018255","https://openalex.org/W2008901888"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}